As ratification stutters for the Comprehensive Economic and Trade Agreement (CETA), the much-maligned free-trade deal between Canada and the European Union, debate continues as to whether the Canadian intellectual property…
Tag: CETA
in Feature Post, IP, IP Course Topic, IP Intensive, Patents, Pharmaceutical Drugs, Regulatory Policy1by Editor
1446
CETA: An Opportunity to Fix Canada's Broken Pharmaceutical Patent Linkage System
This is an excerpt from a paper by Adam Falconi, the recipient of the 2015 Barry D. Tomo Memorial Prize for best research paper on a subject related to industrial…
in Access to Medicines, Blogs, Canada, Cross Border Issues, IP, IP Reform, Jurisdiction, Patents, Pharmaceutical Drugs, Regulatory Policy, Trademarks0by Editor
1611
Canada’s IP Laws and the Comprehensive Economic and Trade Agreement (CETA): Canada Got the Short End of the Proverbial Stick
The outline of CETA has arrived – but its full text is still in transit. On what we know of the intellectual property aspects of CETA, Canada got the short…
in Access to Medicines, Canada, Cross Border Issues, European Union, IP, IP Reform, Jurisdiction, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
1798
CETA: A Very Reasonable Canadian-esque Compromise on Pharmaceutical Intellectual Property Law Changes
At long last, the Canadian Federal Government and the European Commission announced in October that a political agreement has been reached regarding the much anticipated Comprehensive Economic and Trade Agreement…
in Access to Medicines, Blogs, Canada, European Union, IP, Patents, Pharmaceutical Drugs, Regulatory Policy, Uncategorized, US, US-Canada Relations0by Editor
1513
Time for a Change? Fraser Institute Urges Canada to Strengthen its Pharmaceutical IP Laws
A little over a week ago, the Fraser Institute, a prominent and independent Canadian public policy think tank, released a report calling for a strengthening of intellectual property protection for…
in Copyright, Copyright Reform, European Union, IP, IP Reform, Patents, Pharmaceutical Drugs, Supreme Court of Canada, Trademarks, US, US-Canada Relations, WIPO0by Editor
1790
A Cautionary Kudos: Canada Moves Up on USTR IP Watch List
Earlier this month, the United States Trade Representative (USTR) released its annual “Special 301 Report,” which evaluates the intellectual property rights (IPR) protection and enforcement of its trading partners. Over…